Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...

Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Wrestling sectionals were held over the weekend and Marion-area competitors earned berths into the upcoming district ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Assembly Bio said that it plans to advance ABI-1179 directly into the Phase 1b portion of the study, which will include ...

Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...